FOXO1, a tiny protein with intricate interactions: Promising therapeutic candidate in lung cancer

• Published in: Biomedicine & pharmacotherapy Vol. 169; p. 115900
• Main Authors: Ebrahimnezhad, Mohammad, Natami, Mohammad, Bakhtiari, Ghazaleh Hafezi, Tabnak, Peyman, Ebrahimnezhad, Niloufar, Yousefi, Bahman, Majidinia, Maryam
• Format: Journal Article
• Language: English
• Published: Elsevier Masson SAS 31-12-2023; Elsevier
• Subjects: FOXO1; Lung cancer; NcRNAs; Signaling pathways; Transcription factors; NcRNAs; Signaling pathways; Transcription factors; Lung cancer; FOXO1
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115900

Nowadays, lung cancer is the most common cause of cancer-related deaths in both men and women globally. Despite the development of extremely efficient targeted agents, lung cancer progression and drug resistance remain serious clinical issues. Increasing knowledge of the molecular mechanisms underlying progression and drug resistance will enable the development of novel therapeutic methods. It has been revealed that transcription factors (TF) dysregulation, which results in considerable expression modifications of genes, is a generally prevalent phenomenon regarding human malignancies. The forkhead box O1 (FOXO1), a member of the forkhead transcription factor family with crucial roles in cell fate decisions, is suggested to play a pivotal role as a tumor suppressor in a variety of malignancies, especially in lung cancer. FOXO1 is involved in diverse cellular processes and also has clinical significance consisting of cell cycle arrest, apoptosis, DNA repair, oxidative stress, cancer prevention, treatment, and chemo/radioresistance. Based on the critical role of FOXO1, this transcription factor appears to be an appropriate target for future drug discovery in lung cancers. This review focused on the signaling pathways, and molecular mechanisms involved in FOXO1 regulation in lung cancer. We also discuss pharmacological compounds that are currently being administered for lung cancer treatment by affecting FOXO1 and also point out the essential role of FOXO1 in drug resistance. Future preclinical research should assess combination drug strategies to stimulate FOXO1 and its upstream regulators as potential strategies to treat resistant or advanced lung cancers.
[Display omitted]